Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.
14h
Regenxbio Meets Primary Endpoint in Duchenne Muscular Dystrophy Study, Swings to 1Q Loss -- Update
Regenxbio met its primary endpoint in a Phase 3 study of its Duchenne muscular dystrophy treatment, but it swung to a first-quarter loss as revenue plunged. Shares fell 20% to $8.06 in premarket ...
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months under the weight of a ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Dyne Therapeutics said Monday its ...
Dutch Bros’ annual “Drink One for Dane” fundraiser returns Friday, May 15, with the coffee chain bringing back its ...
The Muscular Dystrophy Association (MDA) today announced a $100,000 investment by BridgeBio to strengthen multidisciplinary care for people living with limb-girdle muscular dystrophy (LGMD). Through ...
Muscle tissue damage appears when muscular dystrophy is induced in a mouse model (middle). But when researchers block the function of two genes that drive unwanted mitochondrial pore formation (right) ...
PHOENIX - We are learning more about the death of comedian Gilbert Gottfried, which was announced on April 12. According to a statement from Gottfried's longtime friend and publicist, Glenn Schwartz, ...
Muscular dystrophies represent a group of inherited primary diseases of muscle, characterized by muscle fiber degeneration and muscle weakness. Classification of these conditions has traditionally ...
The first gene therapy for children with Duchenne muscular dystrophy has been approved by the U.S. Food and Drug Administration. The therapy can be used in 4- and 5-year-olds with the degenerative ...
Regenxbio said top-line results showed it met its primary endpoint in a Phase 3 study of its RGX-202 gene therapy for Duchenne Muscular Dystrophy. The trial met its primary endpoint with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results